Small-sized polymeric micelles incorporating docetaxel suppress distant metastases in the clinically-relevant 4T1 mouse breast cancer model

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Li, Yunfei ^a,b   Jin, Mingji ^a   Shao, Shuai ^a,c   Huang, Wei ^a   Yang, Feifei ^a   Chen, Wei ^a   Zhang, Shenghua ^b   Xia, Guimin ^b   Gao, Zhonggao ^a  

^a INSTITUTE OF MATERIA MEDICA   (China)

^b INSTITUTE OF MEDICINAL BIOTECHNOLOGY   (China)

^c YANBIAN UNIVERSITY   (China)

Author keywords

4T1 Mammary carcinoma; Docetaxel; Malignant breast cancer; Metastasis; Primary tumor resected; Small sized polymeric micelles

Indexed keywords

DOCETAXEL; DUOPAFEI; MACROGOL 2000; NANOCARRIER; POLYETHYLENE GLYCOL METHOXY B POLYLACTIDE; POLYLACTIDE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; DRUG CARRIER; MACROGOL DERIVATIVE; MICELLE; MONOMETHOXYPOLYETHYLENE GLYCOL; NANOPARTICLE; POLYESTER; POLYMER; TAXOID;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOLUMINESCENCE; BREAST CANCER; CANCER CHEMOTHERAPY; CELL ENCAPSULATION; CONTROLLED STUDY; DISTANT METASTASIS; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG MECHANISM; FEMALE; HISTOLOGY; LUNG EXAMINATION; METASTASIS INHIBITION; MICELLE; MOUSE; NEUTROPHIL; NONHUMAN; PARTICLE SIZE; SMALL SIZED POLYMERIC MICELLES; TUMOR CELL; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ANIMAL; APOPTOSIS; BAGG ALBINO MOUSE; BREAST NEOPLASMS; CHEMISTRY; COMPARATIVE STUDY; DOSE RESPONSE; DRUG EFFECTS; LUNG NEOPLASMS; MEDICINAL CHEMISTRY; PATHOLOGY; SECONDARY; TIME; TUMOR CELL LINE; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; CHEMISTRY, PHARMACEUTICAL; CHEMOTHERAPY, ADJUVANT; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG CARRIERS; FEMALE; LUNG NEOPLASMS; MICE, INBRED BALB C; MICELLES; NANOPARTICLES; NEOADJUVANT THERAPY; POLYESTERS; POLYETHYLENE GLYCOLS; POLYMERS; TAXOIDS; TIME FACTORS; TUMOR BURDEN;

EID: 84900837802     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-329     Document Type: Article

References (52)

1. Parker B, Sukumar S. Distant metastasis in breast cancer: molecular mechanisms and therapeutic targets. Cancer Biol Ther 2003, 2(1):14-21.
2. Gong C, Yang B, Qian Z, Zhao X, Wu Q, Qi X, Wang Y, Guo G, Kan B, Luo F. Improving intraperitoneal chemotherapeutic effect and preventing postsurgical adhesions simultaneously with biodegradable micelles. Nanomedicine 2012, 8(6):963-973. 10.1016/j.nano.2011.10.010, 22154531.
3. Kataoka K, Harada A, Nagasaki Y. Block copolymer micelles for drug delivery: design, characterization and biological significance. Adv Drug Deliv Rev 2012, 47(1):113-131.
4. Zhang L, Gu F, Chan J, Wang A, Langer R, Farokhzad O. Nanoparticles in medicine: therapeutic applications and developments. Clin Pharmacol Ther 2007, 83(5):761-769.
5. Davis ME. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov 2008, 7(9):771-782. 10.1038/nrd2614, 18758474.
6. Dobrovolskaia MA, McNeil SE. Immunological properties of engineered nanomaterials. Nat Nanotechnol 2007, 2(8):469-478. 10.1038/nnano.2007.223, 18654343.
7. Gradishar WJ, Tjulandin S, Davidson N, Shaw H, Desai N, Bhar P, Hawkins M, O'Shaughnessy J. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 2005, 23(31):7794-7803. 10.1200/JCO.2005.04.937, 16172456.
8. Wong C, Stylianopoulos T, Cui J, Martin J, Chauhan VP, Jiang W, Popović Z, Jain RK, Bawendi MG, Fukumura D. Multistage nanoparticle delivery system for deep penetration into tumor tissue. Proc Natl Acad Sci 2011, 108(6):2426-2431. 10.1073/pnas.1018382108, 3038705, 21245339.
9. Jain RK, Stylianopoulos T. Delivering nanomedicine to solid tumors. Nat Rev Clin Oncol 2010, 7(11):653-664. 10.1038/nrclinonc.2010.139, 3065247, 20838415.
10. Volk LD, Flister MJ, Chihade D, Desai N, Trieu V, Ran S. Synergy of nab-paclitaxel and bevacizumab in eradicating large orthotopic breast tumors and preexisting metastases. Neoplasia 2011, 13(4):327. 3071081, 21472137.
11. O'brien M, Wigler N, Inbar M, Rosso R, Grischke E, Santoro A, Catane R, Kieback D, Tomczak P, Ackland S. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX™/Doxil®) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol 2004, 15(3):440-449. 10.1093/annonc/mdh097, 14998846.
12. Fang J, Nakamura H, Maeda H. The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Deliv Rev 2011, 63(3):136-151. 10.1016/j.addr.2010.04.009, 20441782.
13. Schroeder A, Heller DA, Winslow MM, Dahlman JE, Pratt GW, Langer R, Jacks T, Anderson DG. Treating metastatic cancer with nanotechnology. Nat Rev Cancer 2011, 12(1):39-50. 10.1038/nrc3180, 22193407.
14. Peiris PM, Toy R, Doolittle E, Pansky J, Abramowski A, Tam M, Vicente P, Tran E, Hayden E, Camann A. Imaging metastasis using an integrin-targeting chain-shaped nanoparticle. ACS Nano 2012, 6(10):8783-8795. 10.1021/nn303833p, 3487383, 23005348.
15. Chen SL, Iddings DM, Scheri RP, Bilchik AJ. Lymphatic mapping and sentinel node analysis: current concepts and applications. CA Cancer J Clin 2006, 56(5):292-309. 10.3322/canjclin.56.5.292, 17005598.
16. Tammela T, Saaristo A, Holopainen T, Ylä-Herttuala S, Andersson LC, Virolainen S, Immonen I, Alitalo K. Photodynamic ablation of lymphatic vessels and intralymphatic cancer cells prevents metastasis. Sci Transl Med 2011, 3(69):69ra11-69ra11.
17. Weinberg RA. The biology of cancer, vol. 255 2007, New York: Garland Science.
18. Anderson C, Jacobson G, Bhatia S, Buatti JM. Atlas of Diagnostic Oncology. Int J Radiat Oncol Biol Phys 2011, 81(1):314-314.
19. Tang N, Du G, Wang N, Liu C, Hang H, Liang W. Improving penetration in tumors with nanoassemblies of phospholipids and doxorubicin. J Natl Cancer Inst 2007, 99(13):1004-1015. 10.1093/jnci/djm027, 17596572.
20. Qin L, Zhang F, Lu X, Wei X, Wang J, Fang X, Si D, Wang Y, Zhang C, Yang R. Polymeric micelles for enhanced lymphatic drug delivery to treat metastatic tumors. J Control Release 2013, 171(2):133-142. 10.1016/j.jconrel.2013.07.005, 23863448.
21. Rafi M, Cabral H, Kano M, Mi P, Iwata C, Yashiro M, Hirakawa K, Miyazono K, Nishiyama N, Kataoka K. Polymeric micelles incorporating (1, 2-diaminocyclohexane) platinum (II) suppress the growth of orthotopic scirrhous gastric tumors and their lymph node metastasis. J Control Release 2012, 159(2):189-196. 10.1016/j.jconrel.2012.01.038, 22326402.
22. Wei X, Wang Y, Zeng W, Huang F, Qin L, Zhang C, Liang W. Stability Influences the Biodistribution, Toxicity, and Anti-tumor Activity of Doxorubicin Encapsulated in PEG-PE Micelles in Mice. Pharm Res 2012, 29(7):1977-1989. 10.1007/s11095-012-0725-5, 22426964.
23. Bae YH, Yin H. Stability issues of polymeric micelles. J Control Release 2008, 131(1):2-4. 10.1016/j.jconrel.2008.06.015, 18625275.
24. Wang Y, Wang R, Lu X, Lu W, Zhang C, Liang W. Pegylated phospholipids-based self-assembly with water-soluble drugs. Pharm Res 2010, 27(2):361-370. 10.1007/s11095-009-0029-6, 20033475.
25. Rowinsky EK, Donehower RC. Paclitaxel (Taxol). N Engl J Med 1995, 332(15):1004-1014. 10.1056/NEJM199504133321507, 7885406.
26. Miller KD, Sledge GW. Taxanes in the Treatment of Breast Cancer: A Prodigy Comes of Age. Cancer Invest 1999, 17(2):121-136. 10.3109/07357909909011727, 10071597.
27. Bhalla KN. Microtubule-targeted anticancer agents and apoptosis. Oncogene 2003, 22(56):9075-9086. 10.1038/sj.onc.1207233, 14663486.
28. CHABNER BA LONGODL. Cancer chemotherapy & biotherapy. Principles & practice 2001,
29. Jones S. Head-to-head: docetaxel challenges paclitaxel. Eur J Cancer Suppl 2006, 4(4):4-8.
30. Araque Arroyo P, Ubago Pérez R, Cancela Díez B, Fernández Feijóo MA, Hernández Magdalena J, Calleja Hernández MA. Controversies in the management of adjuvant breast cancer with taxanes: Review of the current literature. Cancer Treat Rev 2011, 37(2):105-110. 10.1016/j.ctrv.2010.06.002, 20655664.
31. Kim D-W, Kim S-Y, Kim H-K, Kim S-W, Shin S, Kim J, Park K, Lee M, Heo D. Multicenter phase II trial of Genexol-PM, a novel Cremophor-free, polymeric micelle formulation of paclitaxel, with cisplatin in patients with advanced non-small-cell lung cancer. Ann Oncol 2007, 18(12):2009-2014. 10.1093/annonc/mdm374, 17785767.
32. Kim SC, Kim DW, Shim YH, Bang JS, Oh HS, Kim SW, Seo MH. In vivo evaluation of polymeric micellar paclitaxel formulation: toxicity and efficacy. J Control Release 2001, 72(1):191-202.
33. Kim T-Y, Kim D-W, Chung J-Y, Shin SG, Kim S-C, Heo DS, Kim NK, Bang Y-J. Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies. Clin Cancer Res 2004, 10(11):3708-3716. 10.1158/1078-0432.CCR-03-0655, 15173077.
34. Lee KS, Chung HC, Im SA, Park YH, Kim CS, Kim S-B, Rha SY, Lee MY, Ro J. Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer. Breast Cancer Res Treat 2008, 108(2):241-250. 10.1007/s10549-007-9591-y, 17476588.
35. Zhang X, Jackson JK, Burt HM. Development of amphiphilic diblock copolymers as micellar carriers of taxol. Int J Pharm 1996, 132(1):195-206.
36. Liggins R, Burt H. Polyether-polyester diblock copolymers for the preparation of paclitaxel loaded polymeric micelle formulations. Adv Drug Deliv Rev 2002, 54(2):191-202. 10.1016/S0169-409X(02)00016-9, 11897145.
37. Pulaski BA, Ostrand-Rosenberg S. Mouse 4T1 breast tumor model. Curr Protoc Immunol 2001, 20.22. 21-20.22. 16.
38. Eckhardt BL, Francis PA, Parker BS, Anderson RL. Strategies for the discovery and development of therapies for metastatic breast cancer. Nat Rev Drug Discov 2012, 11(6):479-497. 10.1038/nrd2372, 22653217.
39. Rashid OM, Nagahashi M, Ramachandran S, Graham L, Yamada A, Spiegel S, Bear HD, Takabe K. Resection of the primary tumor improves survival in metastatic breast cancer by reducing overall tumor burden. Surgery 2013, 153(6):771-778. 10.1016/j.surg.2013.02.002, 23489938.
40. Xiao L, Xiong X, Sun X, Zhu Y, Yang H, Chen H, Gan L, Xu H, Yang X. Role of cellular uptake in the reversal of multidrug resistance by PEG-b-PLA polymeric micelles. Biomaterials 2011, 32(22):5148-5157. 10.1016/j.biomaterials.2011.03.071, 21546083.
41. Luo Y, Ling Y, Guo W, Pang J, Liu W, Fang Y, Wen X, Wei K, Gao X. Docetaxel loaded oleic acid-coated hydroxyapatite nanoparticles enhance the docetaxel-induced apoptosis through activation of caspase-2 in androgen independent prostate cancer cells. J Control Release 2010, 147(2):278-288. 10.1016/j.jconrel.2010.07.108, 20655966.
42. Tao K, Fang M, Alroy J, Sahagian GG. Imagable 4T1 model for the study of late stage breast cancer. BMC Cancer 2008, 8(1):228. 10.1186/1471-2407-8-228, 2529338, 18691423.
43. Jenkins DE, Yu S-F, Hornig YS, Purchio T, Contag PR. In vivo monitoring of tumor relapse and metastasis using bioluminescent PC-3 M-luc-C6 cells in murine models of human prostate cancer. Clin Exp Metastasis 2003, 20(8):745-756.
44. Sheikh AY, Lin SA, Cao F, Cao Y, Van der Bogt KE, Chu P, Chang CP, Contag CH, Robbins RC, Wu JC. Molecular imaging of bone marrow mononuclear cell homing and engraftment in ischemic myocardium. Stem Cells 2007, 25(10):2677-2684. 10.1634/stemcells.2007-0041, 3657503, 17628019.
45. Joyce JA, Pollard JW. Microenvironmental regulation of metastasis. Nat Rev Cancer 2008, 9(4):239-252. 3251309, 19279573.
46. Aslakson CJ, Miller FR. Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res 1992, 52(6):1399-1405.
47. Pulaski BA, Smyth MJ, Ostrand-Rosenberg S. Interferon-γ-dependent phagocytic cells are a critical component of innate immunity against metastatic mammary carcinoma. Cancer Res 2002, 62(15):4406-4412.
48. Harris J, Morrow M, Norton L. Malignant tumors of the breast. Cancer Principles Pract Oncol 1997, 2:1557-1616.
49. Dykxhoorn DM, Wu Y, Xie H, Yu F, Lal A, Petrocca F, Martinvalet D, Song E, Lim B, Lieberman J. miR-200 enhances mouse breast cancer cell colonization to form distant metastases. PLoS One 2009, 4(9):e7181. 10.1371/journal.pone.0007181, 2749331, 19787069.
50. Harris J, Morrow M, Norton L. Malignant tumors of the breast. Cancer: Principles and Practice of Oncology Philadelphia, PA, Lippincott 1997, 1557-1616.
51. Ostrand-Rosenberg S, Sinha P. Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol 2009, 182(8):4499-4506. 10.4049/jimmunol.0802740, 2810498, 19342621.
52. Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 2009, 30(7):1073-1081. 10.1093/carcin/bgp127, 19468060.